Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:09 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1105–1128 of 1,869 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: First Treatment Period Clear all

Conditions: Androgen Deprivation Therapy, Locally Advanced Prostate Cancer
Interventions: Relugolix and Enzalutamide; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years and older · Male only
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Opioid Induced Constipation
Interventions: Polyethylene Glycol 3350, Movantik; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 84 Years
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 53
States / cities: Huntsville, Alabama • Phoenix, Arizona • Anaheim, California + 46 more

Conditions: Cutaneous T-Cell Lymphoma
Interventions: SGX301 (synthetic hypericin), Placebo; Drug
Lead sponsor: Soligenix; Industry
Eligibility: 18 Years and older
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 33
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 27 more

Conditions: Bladder Cancer
Interventions: cisplatin, fluorouracil, paclitaxel, radiation therapy, Gemcitabine, Radical cystectomy; Drug · Radiation · Procedure
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: Up to 120 Years
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2018
U.S. locations: 2
States / cities: Salt Lake City, Utah

Conditions: Chronic Pain, Chronic Pain Syndrome, Chronic Pancreatitis, Hyperalgesia, Opioid Use Disorder, Opioid-Related Disorders, Opioid Dependence, Chronic Abdominal Pain, ERCP, Pancreatic Surgery
Interventions: Lacosamide; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 5
States / cities: Stanford, California • Indianapolis, Indiana • Rochester, Minnesota + 2 more

Conditions: Alzheimer's Disease
Interventions: Aducanumab (recombinant, fully human anti-Aβ IgG1 mAb), Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 197 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 32
States / cities: Tucson, Arizona • Laguna Hills, California • Lomita, California + 28 more

Conditions: Primary Spontaneous Pneumothorax
Interventions: Autologous Blood Patch; Procedure
Lead sponsor: Rush University Medical Center; Other
Eligibility: 13 Years to 18 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Intervention Group, Treatment as Usual
Interventions: Exercise; Behavioral
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Melanoma
Interventions: Atezolizumab, Atezolizumab Placebo, Cobimetinib, Vemurafenib, Vemurafenib Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 514 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 7
States / cities: Birmingham, Alabama • Tempe, Arizona • Springdale, Arkansas + 4 more

Conditions: Diabetes Mellitus Type II, Hypertension
Interventions: Integrated CHW Intervention, CHW Session 1 Only; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 21 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 2
States / cities: Atlanta, Georgia • New York, New York

Conditions: Non-small Cell Lung Cancer, Lung Cancer, Advanced Malignancies, Carcinoma
Interventions: Brigatinib, Crizotinib; Drug
Lead sponsor: Ariad Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 12
States / cities: Sedona, Arizona • Bellflower, California • Aurora, Colorado + 9 more

Conditions: Cardiovascular Diseases
Interventions: Low polyphenol concentration extra virgin olive oil (EVOO), High polyphenol concentration extra virgin olive oil (EVOO); Dietary Supplement
Lead sponsor: Ralph Hamill; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 3
States / cities: Brunswick, Maine • Rockport, Maine • Scarborough, Maine

Conditions: Tardive Dyskinesia
Interventions: NBI-98854, Placebo; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 48
States / cities: Little Rock, Arkansas • Anaheim, California • Glendale, California + 45 more

Conditions: Multiple Myeloma
Interventions: Pomalidomide, Pegylated Liposomal Doxorubicin (PLD), Dexamethasone; Drug
Lead sponsor: Oncotherapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 8
States / cities: Burbank, California • Encinitas, California • Fresno, California + 5 more

Conditions: Recurrent Respiratory Papillomatosis
Interventions: Avastin® (bevacizumab), Saline; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Spinal Cord Injuries, Neuropathic Pain
Interventions: Non-Interactive Virtual Reality Walking, Interactive Virtual Reality Walking; Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 64 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Systematic Acupuncture
Interventions: Acupuncture Treatments; Procedure
Lead sponsor: NYU Langone Health; Other
Eligibility: 20 Years to 60 Years
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Sepsis, Severe, Septic Shock
Interventions: Smoflipid; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 3
States / cities: Gainesville, Florida • Jacksonville, Florida

Conditions: Healthy Participants
Interventions: TAK-510, TAK-510 Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 124 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Las Vegas, Nevada • Austin, Texas

Conditions: Head and Neck Cancer
Interventions: Radiotherapy, Leucovorin, Cetuximab, Filgrastim, Erythropoetin, Cisplatin, Fluorouracil, Docetaxel; Radiation · Drug · Biological
Lead sponsor: Drexel University College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Immunoglobulin A Nephropathy
Interventions: sparsentan, irbesartan, Dapagliflozin; Drug
Lead sponsor: Travere Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 406 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 40
States / cities: Birmingham, Alabama • Homewood, Alabama • Glendale, California + 34 more

Conditions: Coronary Artery Disease
Interventions: Cangrelor, Placebo; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Acute Liver Failure, Acute Liver Injury
Interventions: Ornithine Phenylacetate; Drug
Lead sponsor: William Lee; Other
Eligibility: 18 Years to 65 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 11
States / cities: San Francisco, California • New Haven, Connecticut • Atlanta, Georgia + 8 more

Conditions: Chronic Illness
Interventions: Virtual Acceptance Commitment Therapy; Behavioral
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 14 Years to 21 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

Relugolix + Enzalutamide Study in High-Risk Prostate Cancer

To Evaluate Patient Preference of Movantik and Polyethylene Glycol 3350 for Opioid Induced Constipation

FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)

Combination Chemotherapy and Radiation Therapy With/Without Surgery In Patients With Stage II/III Bladder Cancer

STTEPP: Safety, Tolerability and Dose Limiting Toxicity of Lacosamide in Patients With Painful Chronic Pancreatitis

Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease

Autologous Blood Patch for Primary Spontaneous Pneumothorax

Caring for Caregivers of Individuals With Alzheimer's Disease

A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma

Scaling Telehealth Models to Improve Co-morbid Diabetes and Hypertension (Phase II)

ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants

A Multicenter Pilot Study to Evaluate the Effect of EVOO on Lipid Parameters

A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia

Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma

Bevacizumab for Treatment of Recurrent Respiratory Papillomatosis (RRP)

Virtual Reality Walking for Neuropathic Pain in Spinal Cord Injury

Acupuncture for Stroke Recovery

LIPIDS-P Trial Phase I/II Trial

A Study of TAK-510 in Healthy Adults

Induction Chemotherapy Followed by Cetuximab and Radiation Therapy for Head and Neck Cancer

A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy

PD and PK Profiles of Switching Between Cangrelor and Ticagrelor Following Ticagrelor Pre-treatment

Safety Study of Ornithine Phenylacetate to Treat Patients With Acute Liver Failure/Severe Acute Liver Injury

Virtual ACT for Adolescent Stress